EUS Guidance Research Articles

Success rate of fiducial marker placement for treatment of esophageal or rectal cancers: a prospective multicenter study (FIDECHO study) (with video)

Background and study aimsEndoscopy Ultra-Sound (EUS)-guided fiducial marker placement in patients with esophageal or rectal cancer who have been referred for radiation therapy lacks data regarding its feasibility and safety. The aim of this study was to assess the success rate of EUS-guided fiducial marker placement in these indications. Patients and methodsThis prospective multicenter study enrolled patients with rectal or esophageal tumor, who were treated between March 2017 and June 2021. The primary endpoint was the success of fiducial markers placement under EUS guidance utilizing the preloaded 22-gauge EchoTip Ultra Fiducial needle® (Cook Medical, Limerick, Ireland), defined by the ability to release fiducials at least at proximal and distal ends of the tumor. The secondary endpoints were the adverse events, length of procedure, and remaining fiducial markers throughout radiation therapy. ResultsA total of 33 patients were included in this study, with a mean age of 64.2 years ±11.3, and 66.7% of males. Twenty patients had rectal adenocarcinoma, and 13 had esophageal malignancies. The success rate of fiducial markers placement was 93.9%. Markers could only be released at the proximal end of the tumor in two cases. The average procedure time (±SD) was 12.5 min (±4.8). The number of fiducial markers placed for each patient was 3.8 (±0.5). No adverse event was reported. At the end of radiotherapy, markers were still visible on imaging in all patients. ConclusionThis prospective multicenter study highlights the safety and high success of the placement of fiducial markers under EUS, for rectal and esophageal tumors, without adverse event, and with a short procedure time. Fiducial markers remain in place over time during radiation therapy. ClinicalTrials.gov ID: NCT03057288

Transluminal antegrade drill dilation technique for hepaticojejunostomy stricture with cholangioscopic evaluation (with video).

Background and study aims Balloon dilation and plastic stent deployment have been performed as hepaticojejunostomy stricture (HJS) treatment techniques under endoscopic ultrasound guidance (EUS). Although these techniques have shown favorable clinical results, the treatment period can be long because stent deployment is required. In addition, HJS may recur even after treatment because the scar tissue itself remains. To overcome these challenges, we developed an EUS-guided antegrade drill dilation technique for treating HJS. The aim of this study was to evaluate the technical feasibility and safety of this technique in terms of the pre- and post-cholangioscopic findings. Patients and methods This retrospective study included consecutive patients whose conditions were complicated with symptomatic HJS between November 2022 and February 2023. Transluminal antegrade drill dilation (TAD) using a novel drill dilator was attempted within 14 days after EUS-guided hepaticogastrostomy (HGS). HJS was diagnosed with cholangioscopy before TAD, and resolution was evaluated after TAD using cholangioscopy. Results TAD was attempted at approximately 11 days after EUS-HGS. The cholangioscope was inserted successfully in all patients after this procedure. Cholangioscopy revealed stricture without evidence of malignancy in 19 patients. In the remaining three patients, stricture was not observed and these patients underwent stent exchange rather than TAD. Among the 19 patients, passage of the guidewire across the HJS into the intestine was unsuccessful in four patients, and the technical success rate for this procedure was 78.9%. TAD was successful in all 15 patients in whom passage of the guidewire was achieved. Conclusions In conclusion, TAD appears to be technically feasible and safe.

A case in which endoscopic ultrasound-guided transrectal drainage was effective for pelvic abscess

The patient, a 33-year-old female, presented to her local doctor with lower abdominal pain. She was referred to our hospital for a plain CT scan, which revealed signs of ileitis. Because acute appendicitis could not be ruled out, the patient was hospitalized. On the third day of hospitalization, she underwent laparoscopic appendicectomy for perforated appendicitis. However, the inflammatory response persisted despite continued antibacterial treatment; we diagnosed this to be due to the formation of a postoperative residual abscess. Since drainage of the abscess was deemed necessary, the patient underwent EUS-guided transrectal drainage on the 26th day of hospitalization. The patient had a favorable postoperative course and was discharged on the 31st day of hospitalization. Along with some literature review, this report details a case in which transrectal drainage under ultrasound endoscopy was effective in treating a pelvic abscess. We report a case of a pelvic abscess that was drained through the rectum under EUS guidance and an internal and external fistula tube was placed. The abscess resolved without complications.

Endoscopic Ultrasound-Guided Fiducial Placement for Stereotactic Body Radiation Therapy in Patients with Pancreatic Cancer.

Accurate delivery of stereotactic body radiotherapy (SBRT) to pancreatic tumors relies on successful EUS-guided placement of fiducial markers. The aim of this study is to report the technical feasibility and safety of EUS-guided fiducial placement and to evaluate the characteristics and technical benefit of SBRT in a cohort of patients with pancreatic cancer (PC). A retrospective chart review was performed for all (n = 82) PC patients referred for EUS-guided fiducial placement by a single endosonographer at a tertiary cancer center. Data regarding EUS-related technical details, SBRT characteristics, adverse events, and continuous visibility of fiducials were recorded and analyzed. Most patients included in the study had either locally advanced disease (32 patients, 39%) or borderline resectable disease (29 patients, 35%). Eighty-two PC patients underwent the placement of 230 fiducial markers under EUS guidance. The technical success rate of the fiducial placement was 98%. No immediate EUS-related adverse events were reported. The average time to the simulation CT after fiducial placement was 3.1 days. Of the 216 fiducial markers used for the SBRT delivery, 202 fiducial markers were visible on both the simulation CT and the cone beam CT scan. A median dose of 40cGY was given to all the patients in five fractions. Of these, 41% of the patients reported no SBRT-related toxicities during the follow-up. Fatigue and nausea were the most reported SBRT-related toxicities, which were seen in 35% of the patients post-SBRT. Our results demonstrate that EUS-guided fiducial placement is safe and effective in target volume delineation, facilitating SBRT delivery in PC patients. Further clinical trials are needed to determine the SBRT-related survival benefits in patients with pancreatic cancer.

EUS-guided coil injection therapy in the management of gastric varices: the first U.S. multicenter experience (with video)

Despite the significant morbidity associated with gastric variceal bleeding, there is a paucity of high-quality data regarding optimal management. EUS-guided coil injection therapy (EUS-COIL) has recently emerged as a promising endoscopic modality for the treatment of gastric varices (GV), particularly compared with traditional direct endoscopic glue injection. Although there are data on the feasibility and safety of EUS-COIL in the management of GV, these have been limited to select centers with particular expertise. The aim of this study was to report the first U.S. multicenter experience of EUS-COIL for the management of GV. This retrospective analysis included patients with bleeding GV or GV at risk of bleeding who underwent EUS-COIL at 10 U.S. tertiary care centers between 2018 and 2022. Baseline patient and procedure-related information was obtained. EUS-COIL entailed the injection of .018 inch or .035 inch hemostatic coils using a 22-gauge or 19-gauge FNA needle. Primary outcomes were technical success (defined as successful deployment of coil into varix under EUS guidance with diminution of Doppler flow), clinical success (defined as cessation of bleeding if present and/or absence of bleeding at 30 days' postintervention), and intraprocedural and postprocedural adverse events. A total of 106 patients were included (mean age 60.4 ± 12.8 years; 41.5% female). The most common etiology of GV was cirrhosis (71.7%), with alcohol being the most common cause (43.4%). Overall, 71.7% presented with acute GV bleeding requiring intensive care unit stay and/or blood transfusion. The most common GV encountered were isolated GV type 1 (60.4%). A mean of 3.8 ± 3 coils were injected with a total mean length of 44.7 ± 46.1 cm. Adjunctive glue or absorbable gelatin sponge was injected in 82% of patients. Technical success and clinical success were 100% and 88.7%, respectively. Intraprocedural adverse events (pulmonary embolism and GV bleeding from FNA needle access) occurred in 2 patients (1.8%), and postprocedural adverse events occurred in 5 (4.7%), of which 3 were mild. Recurrent bleeding was observed in 15 patients (14.1%) at a mean of 32 days. Eighty percent of patients with recurrent bleeding were successfully re-treated with repeat EUS-COIL. No significant differences were observed in outcomes between high-volume (>15 cases) and low-volume (<7 cases) centers. This U.S. multicenter experience on EUS-COIL for GV confirms high technical and clinical success with low adverse events. No significant differences were seen between high- and low-volume centers. Repeat EUS-COIL seems to be an effective rescue option for patients with recurrent bleeding GV. Further prospective studies should compare this modality versus other interventions commonly used for GV.

Novel use of lumen-apposing metal stent for recanalization of complete stenosis of colo-colonic anastomosis.

Combined antegrade-retrograde dilation [1] is an established technique that has been adapted for benign colonic obstruction [2] [3] but requires use of accessory devices and predilation followed by deployment of self-expanding metal stents [2] [3]. Rendezvous sigmoidorectal reanastomosis using a lumen-apposing metal stent (LAMS) has also been described with endosonographic (EUS) guidance [4]. We hereby report a recanalization of complete stenosis of a colo-colonic anastomosis without EUS guidance.

EUS-guided coil placement and cyanoacrylate glue injection for gastric variceal bleeding with obvious spontaneous portosystemic shunts.

Ectopic embolism caused by cyanoacrylate glue for the treatment of gastric varices with obvious spontaneous portosystemic shunts is a serious complication of endoscopic therapy. This study was performed to investigate the safety and therapeutic effect of EUS-guided coil placement and cyanoacrylate glue injection for gastric varices with obvious spontaneous portosystemic shunts. Six patients with gastric variceal bleeding and obvious spontaneous portosystemic shunts were included in this study. We evaluated the success rate of variceal occlusion after intraoperative embolization, the postoperative rebleeding rate at 48 h and 2 weeks posttreatment, and the incidence of ectopic embolism and other adverse events. Gastroscopy and computed tomography portal venography (CTPV) were performed 7 months later. All patients underwent successful coil placement and cyanoacrylate glue injection under EUS guidance. The blood flow was confirmed by Doppler examination, the target vessels were successfully blocked, and no rebleeding had occurred at 48 h or 2 weeks after endoscopic treatment. Gastroscopy was repeated 7 months after endoscopic treatment, revealing local ulcer formation. CTPV was also repeated 7 months after endoscopic treatment, showing that the coils were present in the target vessels with no displacement, the portosystemic shunt vessels were occluded, and no ectopic embolization had occurred. The coil placement combined with cyanoacrylate glue embolism is a safe and effective method for patients with gastric variceal bleeding and obvious spontaneous portosystemic shunts.

EUS-guided through-the-needle microforceps biopsy for diagnosis of tubercular lymphadenitis mimicking pancreatic cystic lesion (with video).

A 40-year-old male presented with upper abdominal discomfort and ultrasound abdomen revealed a cystic lesion in the uncinate process. Contrast-enhanced computed tomography revealed a thick-walled cystic lesion measuring 4.2 cm in the uncinate process [Figure 1]. Positron emission computed tomography revealed flouro-deoxyglucose avidity in the wall of this cystic lesion [Figure 2]. EUS-guided fine-needle biopsy from the cystic lesion done elsewhere was inconclusive on two separate occasions. EUS done at our center revealed a complex cystic lesion posterior to the head of the pancreas and closely abutting the inferior vena cava with normal uncinate process [Figure 3; arrows]. Contrast-enhanced harmonic EUS using Sonovue (Bracco, Milan, Italy) at low mechanical index of 0.12 revealed nonhomogenous enhancement of the cystic lesion with solid areas showing enhancement [arrows; Figure 4] and anechoic areas not enhancing. EUS-guided fine-needle biopsy form the solid as well as liquid areas was inconclusive and revealed necrosis only. Thereafter, tissue sampling was done from the solid area of the lesion under EUS guidance using through the needle forceps device (Moray Micro Forceps, US Endoscopy, United States) [Figure 5 and Video 1]. To improve the visualization of opening of forceps in the lesion, biopsy was performed using both B mode and harmonic EUS [Video 1]. The use of harmonic EUS led on to better visualization of the tip of Microforceps. Two passes were taken and crush smear was prepared with one specimen and the other specimen was sent in formalin vial. The cytopathological examination revealed lymphoid tissue with the presence of loose collection of epitheloid cells and necrosis [Figure 6]. No acid fast bacilli could be detected. The rapid nucleic acid amplification test (Xpert MTB/RIF; Cepheid, Sunnyvale, CA, USA) performed on the aspirated specimen was negative. The Mantoux test was positive (induration of 16 mm), C-reactive protein was elevated (16 mg/L), and the patient was started on anti-tubercular therapy (ATT). The patient responded to ATT and the abdominal discomfort subsided after 1 month of initiating ATT. Serum CRP normalized at 2 months and ultrasound of the abdomen done three months after initiation of ATT revealed reduction in size of the lesion (2.3 cm).Figure 1: Contrast enhanced computed tomography: thick walled cystic lesion in the uncinate process of pancreasFigure 2: Positron emission computed tomography: flouro-deoxyglucose avidity in the wall of cystic lesionFigure 3: EUS: Complex cystic lesion (arrows) posterior to the head of pancreas and closely abutting the inferior vena cava with normal uncinate processFigure 4: Contrast-enhanced harmonic EUS: Nonhomogenous enhancement of the cystic lesion with solid areas showing enhancement (arrows) and anechoic areas not enhancingFigure 5: EUS-guided biopsy using through the needle forceps deviceFigure 6: Microphotograph of microbiopsy specimen: a loose collection of epithelioid cells (arrows) with necrosis in the background (H and E, ×40)To improve the diagnostic yield of EUS-guided tissue sampling, through-the-needle micro-forceps device has been introduced and studies have reported high diagnostic yield in pancreatic cystic lesions.[1,2] It can also be used for tissue diagnosis in difficult to diagnose lesions as in the index case. Declaration of patient consent The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient has given his consent for his images and other clinical information to be reported in the journal. The patient understands that his name and initials will not be published and due efforts will be made to conceal his identity, but anonymity cannot be guaranteed. Financial support and sponsorship Nil. Conflicts of interest Surinder Singh Rana is an Editorial Board Member of the journal. This article was subject to the journal’s standard procedures, with peer review handled independently of this editor and his research group.

Current status of endoscopic ultrasound-guided antegrade intervention for biliary diseases in patients with surgically altered anatomy.

Endoscopic management of biliary diseases in patients with surgically altered anatomy can be challenging because the altered anatomy makes it difficult to insert an endoscope into the biliary orifice. Even if insertion is feasible, the worse maneuverability of the endoscope and the restriction in available devices and techniques could complicate the procedure. Recently, endoscopic ultrasound-guided antegrade intervention (EUS-AG) has been reported as a useful management method for biliary diseases, especially in patients with surgically altered anatomy. In EUS-AG, the biliary disease is managed in an antegrade fashion through a temporal fistula created under EUS guidance between the intrahepatic biliary duct and upper intestine. In this article, we reviewed the current status of EUS-AG for each biliary diseases, malignant biliary obstruction, bile duct stones, and benign biliary stricture in patients with surgically altered anatomy.

Safety of teaching endoscopic ultrasound-guided gastroenterostomy (EUS-GE) can be improved with standardization of the technique.

Abstract Background and study aims Endoscopic ultrasound-guided gastroenterostomy (EUS-GE) is a novel technique developed to manage gastric outlet obstruction (GOO). It involves creating a fistula between the stomach and the proximal small bowel using an electric cautery-enhanced lumen-apposing metal stent (ECE-LAMS) with EUS guidance. We aimed to publish our experience in improving teaching of this technique to practicing endoscopists with a wide range of experience by comparing the outcomes before and after standardization of procedural steps. Methods All EUS-GEs performed for inoperable GOO at a single institution from 2014 to 2021 were retrospectively analyzed. The technique was taught by one experienced endoscopist with prior expertise. Five advanced endoscopists with prior EUS and ECE-LAMS placement experience participated. The impact of standardization on outcomes (clinical and technical success, length of stay [LOS], procedure time, and adverse events [AEs]) was compared. Results A total 41 EUS-GEs were performed (5 before and 36 after standardization) by endoscopists with practice experience ranging from 2 to 13 years. The patient population was similar in age and sex. Standardization was associated with significantly higher rates of technical success (100 % vs 60 %, P = 0.01) and lower peri-procedural AEs (2.8 % vs 40 %, P = 0.03). Two AEs in the pre-standardized group were gastric perforation and gastrocolic fistula creation. One AE in the post-standardized group was gastric perforation. Procedure time, clinical success, and LOS showed improvement, although it was not statistically significant. Conclusions Teaching EUS-GE after standardizing the procedure was associated with a significant increase in technical success and a decrease in AEs irrespective of prior total experiences.

EUS-guided drainage of the pancreatic duct for the treatment of postoperative stenosis of pancreatico-digestive anastomosis or pancreatic duct stenosis complicating chronic pancreatitis: Experience at a tertiary care center.

Background and Objectives:For the treatment of pancreatic duct stenosis due to chronic pancreatitis (CP) or postoperative (PO) stenosis, endoscopic procedures are usually the first choice. In cases of failure of the recommended treatment by ERCP, anastomosis between the Wirsung duct and the stomach or duodenum can be performed under EUS guidance. The objective of this retrospective study was to compare the outcomes of pancreatico-gastric or pancreaticoduodenal anastomosis under EUS for PO stenosis versus CP stenosis.Subjects and Methods:This was a retrospective, single-center, consecutive case study of patients who underwent EUS-guided Wirsungo-gastric/bulbar anastomosis.Results:Forty-three patients were included. Twenty-one patients underwent treatment for PO stenosis, and 22 patients underwent treatment for CP stenosis. The technical success rate was 95.3% (41/43), with 100% in cases of PO stenosis and 90.9% in cases of CP stenosis. The clinical success rate was 72.5% (29/40): 75% (15/20) in cases of PO stenosis and 70% (14/20) in cases of CP stenosis. The overall morbidity rate was 34.9% (15/43). The main complication was postprocedural pain, occurring in 20.9% (9/443) of patients. The rate of stent migration or obstruction was 27.9% (12/43). There was no difference in patient outcomes or morbidity according to the etiology of the stenosis. The median follow-up duration in this study was 14 months.Conclusions:EUS-guided Wirsungo-gastric/duodenal anastomosis is a feasible, minimally invasive, safe, and relatively effective procedure. The rates of technical success, clinical success, and complications were not different between patients with PO and CP stenosis. However, the follow-up period was too short to assess recurrent symptoms in these patients.

Endoscopic Ultrasound-Guided Acquisition of Portal Venous Circulating Tumor Cells as a Potential Diagnostic and Prognostic Tool for Pancreatic Cancer.

BackgroundCirculating tumor cells (CTCs) were a promising liquid biopsy for pancreatic cancer (PC) but circulate in low counts in peripheral blood. We evaluated the diagnostic and prognostic values of portal vein (PoV) CTCs in PC patients.MethodsPoV was aspirated under EUS guidance from 40 patients with suspected pancreaticobiliary cancers. Epithelial–mesenchymal-transition-related subtypes of CTCs were identified via immunofluorescence using EpCAM and Twist antibodies. The diagnostic and prognostic performance of PoV CTCs was investigated by receiver-operating characteristic (AUC) curve and Kaplan–Meier survival analysis.ResultsIn total, 40 patients including 31 with PC, 4 with non-pancreatic periampullary cancer and 5 with benign pancreatic diseases (BPD) were enrolled. CTCs were detected more in PoV compared with peripheral blood. PoV CTC numbers in BPD patients were lower than in PC patients. The number of PoV CTCs, especially mesenchymal-CTCs (M-CTCs), was positively correlated with the tumor burden, instead of epithelial-CTCs (E-CTCs). The combination of PoV CTC numbers and CA19-9 demonstrated better diagnostic efficiency (AUC value 0.987) than either alone in differentiating PC with BPD. Moreover, the diagnostic efficacy of PoV CTCs and M-CTCs were obviously better than that of E-CTCs and CA19-9 in distinguishing early and late stage PC. Lastly, high PoV CTC and M-CTC numbers were both associated with shorter overall survival.ConclusionAcquisition of the PoV samples in PC patients via EUS-guided procedures has been proved safe and feasible. PoV CTCs, especially M-CTCs, have great potentials in diagnosing and predicting the prognosis of PC, especially in combination with CA19-9.

S1694 IgG4-Related Sclerosing Cholangitis - An EUS Diagnosis

Introduction: Sclerosing cholangitis is a heterogenous disease associated with choledocholithiasis, biliary tumor or infection. The participation of IgG4 subclass in the pathology of sclerosing cholangitis is typically associated with autoimmune pancreatitis (60%), sialadenitis (34%), tubulo-interstitial nephritis (23%) and peri-aortitis (20%). Isolated lower duct IgG4 related sclerosing cholangitis (IgG4-Sc) is extremely uncommon and we present one such rare case. Case Description/Methods: A 73-year-old former smoker presents with complaints of yellowish discoloration of the skin and decreased appetite for a month. He has lost 44 lbs and endorses diarrhea. His family history is remarkable for lung cancer and kidney disease. Laboratory data shows cholestatic jaundice- total bilirubin of 14.2 mg/dL, AST 61 U/L, ALT 60 U/L and Alkaline phosphatase 328 U/L. CT Abdomen and Pelvis shows intra and extra-hepatic biliary ductal dilatation with common bile duct distension up to 1.4 cm. Subsequent MRCP notable for focal wall thickening involving the mid and lower portion of the common bile duct causing severe stenosis, concerning for CBD malignancy. ERCP shows proximal dilatation of the CBD with stricture of the distal end of bile duct. Biopsies obtained from the stricture were negative and tumor markers showed CEA 2.4 and CA 19-9 212. ANA screen was positive with high DsDNA antibody and elevated IgG4 at 761 mg/dL. Serum lipase was normal, anti-smooth muscle antibody and anti-mitochondrial antibody were negative. He subsequently underwent EUS/ERCP, and the CBD stricture and peri-portal lymph nodes were biopsied. Pathology from CBD stricture showed fibrosis and chronic inflammation with increased IgG4 positive plasma cells by immunohistochemistry. Hence, the patient was diagnosed with IgG4-related sclerosing cholangitis and initiated on 40 mg of Prednisone. Discussion: IgG4 related disease is a multiorgan fibro-inflammatory disease that involves infiltration of IgG4 positive plasma cells into multiple organs. IgG4-Sc is observed in elderly men who present with obstructive jaundice. HISORt criteria is used to make the diagnosis and was initially designed for diagnosis of autoimmune pancreatitis. Radiographically, Type 1 IgG4-Sc involves stenosis of only the lower bile duct and may resemble cholangiocarcinoma. Additionally, IgG4 levels may be normal further confounding the diagnostic picture. A high degree of clinical suspicion and biopsy (via EUS guidance or cholangioscopy) is imperative in making a diagnosis.Figure 1.: Endoscopic ultrasound revealing pancreatic body pseudocyst measuring 11x10 cm in diameter.

Living on the EDGE: Canadian Experience With EUS-directed Transgastric ERCP (EDGE) in Patients With Roux-en-Y Gastric Bypass Anatomy.

IntroductionRoux-en-Y gastric bypass (RYGB) surgery imposes anatomic barriers to endoscopic retrograde cholangiopancreatography (ERCP). Potential options for biliary access in these patients include laparoscopic-assisted ERCP or balloon enteroscopy. However, these approaches require specialized equipment and/or operating room personnel and are associated with high rates of failure and adverse events compared to conventional ERCP. A recently described technique, EDGE, is an endoscopic approach which involves accessing the excluded stomach to facilitate ERCP.ObjectiveThe objective of this study is to describe the results of EDGE procedures performed in Canada.MethodsData were collected from patient cases who had undergone an EDGE procedure across centers in Canada. All patients had a history of RYGB bariatric surgery. In each procedure, a 20-mm diameter lumen-apposing metal stent (LAMS) was deployed under EUS guidance to allow access from the gastric remnant/proximal jejunum to the excluded stomach. Subsequently, during a separate procedure, a duodenoscope was passed through the LAMS to perform ERCP. Following ERCP, the LAMS was replaced with a pigtail stent or APC was used to facilitate closure of the gastro-jejunal/gastro-gastric fistula.ResultsThe indication for EDGE in the seven included cases was for the treatment of choledocholithiasis (six) or gallstone pancreatitis (one). The technical success rate of the EDGE procedure in these cases was 100%. Clinical success, defined by normalization of bilirubin and symptomatic relief, was observed in all cases. There were no adverse events reported.ConclusionThe results of this series support EDGE as a safe and minimally invasive approach to biliary access and therapy in patients with previous RYGB surgery.

EUS-guided fiducial marker insertion for radiotherapy in advanced esophageal carcinoma: submucosal insertion may lead to less migration when compared to intratumoral insertion.

The use of radiotherapy is frequently required in the treatment of locally advanced esophageal squamous cell carcinoma. However, the margins of the tumor are often difficult to ascertain on computed tomography. Thus, EUS-guided fiducial marker insertion can aid the localization of the margins of the tumor. However, the optimal technique of the procedure is still uncertain. This was a retrospective study of all patients that received EUS-guided fiducial marker insertion between March 2015 and December 2018. All patients suffering from esophageal squamous cell carcinoma scheduled for radiotherapy underwent the procedure within one week of the scheduled appointment. Gold fiducial markers were inserted under EUS guidance either intratumorally or within the submucosa just proximal and distal to the tumor. Outcome parameters included tumor characteristics, early and late migration rates, and tumor response rates. During the study period, 40 patients were recruited. 10 fiducial markers were placed intratumorally and 30 markers were placed submucosally. When comparing fiducials that were placed in the submucosa versus intratumorally, significantly more fiducials had early (40% vs 0%, RR = 0.6, 95% CI 0.36, 1.00) and late migration (60% vs 0%, RR = 0.33, 95% CI 0.13, 0.84) in the intratumoral group. The submucosal group had significantly more patients intended for curative intent (96.7% vs 70%, RR = 0.34, 95%CI 0.003, 0.361) and more patients with partial and complete response. There was no difference between the gross tumor volume, the clinical target volume, and the total radiation dose. In esophageal carcinomas planned for radiotherapy, fiducial markers placed in the submucosa may lead to less migration.

ID: 3525459 COMPARING REINTERVENTIONS AND READMISSIONS FOR EUS-GUIDED GASTROJEJUNOSTOMY (GJ) USING LUMEN-APPOSING METAL STENT (LAMS) VS DUODENAL STENT FOR MANAGEMENT OF GASTRIC OUTLET OBSTRUCTION

EUS-guided GJ (EUS-GJ) is a novel technique developed to manage gastric outlet obstruction (GOO). It involves creating a fistulous connection between the stomach and the proximal jejunum using EUS guidance and an electric cautery enhanced (ECE) LAMS. Early literature shows that this technique may have equal efficacy in technical and clinical success compared to duodenal self-expanding metal stent (SEMS). Less is known, however, about the overall readmission and reintervention rates after the initial procedure. This study seeks to better characterize and compare their outcomes.

ID: 3523035 ENDOSCOPIC ULTRASOUND GUIDED GASTROENTEROSTOMY (EUS-GE) VERSUS ENTERAL STENTING (ES) FOR GASTRIC OUTLET OBSTRUCTION (GOO) - A SYSTEMATIC REIVEW AND META-ANALYSIS OF 659 PATIENTS

Background & aims: Gastric outlet obstruction (GOO) can result from a variety of benign and malignant diseases and often leads to nausea, vomiting, and poor oral intake and can preclude the oral delivery of medications. Endoscopic and surgical techniques have been utilized for palliation of GOO. Enteral stenting (ES) is an established technique with high clinical success and low morbidity rate. Endoscopic ultrasound-guided gastroenterostomy (EUS-GE), on the other hand, is a novel approach first described by Fritscher-Ravens et al. in the early 2000s, but clinically adopted after the availability of a bi-flanged lumen-apposing metal stents (LAMS). The technique involves insertion of a LAMS under EUS and fluoroscopic guidance from the stomach to the small bowel distal to the obstruction is a novel approach that aims to provide sustained palliation of GOO. We conducted a comprehensive review and meta-analysis to evaluate the effectiveness in terms of clinical and technical success, as well as the safety profile of EUS-GE and ES.

Role of Endoscopic Ultrasound-Guided Fine-Needle Aspiration of Portal Vein Thrombus in the Diagnosis and Staging of Hepatocellular Carcinoma.

Background/AimsMalignant portal vein thrombus (PVT) is found in up to 44% of patients with hepatocellular carcinoma (HCC). The nature of the thrombus influences treatment selection. The aim of this study was to assess the safety and efficacy of endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) in determining the nature of PVT in liver cirrhosis and/or HCC. MethodsA prospective study was conducted in 34 patients with liver cirrhosis and/or HCC with PVT. Under EUS guidance, PVT was punctured using a 22 G FNA needle (Cook Medical, Bloomington, IN, USA) followed by monitoring of the puncture tract using color Doppler. Patients were followed for adverse events 2 hours after recovery. ResultsThroughout the 30-month study period, 34 patients, including 24 males with a mean age of 59±8 years, were enrolled. There were 8 patients with known HCC and 26 with no liver masses detected by computed tomography (CT). EUS-FNA from PVT was positive for malignancy in 3 patients (8.8%), of which only 1 patient was diagnosed with HCC by CT and 2 patients were newly diagnosed with HCC after EUS-FNA. No major complications were reported. ConclusionsEUS-FNA is a safe and effective technique for determining the nature of PVT that does not fulfill the malignant criteria via imaging studies in patients with liver cirrhosis and/or HCC.

Endoscopic fenestration with EUS guidance for esophageal duplication cyst.

Video 1Endoscopic fenestration of a large esophageal duplication cyst with an electrocautery knife, combined with interventional endosonography techniques to ensure safety.

Focal Autoimmune Pancreatitis: A Simple Flow Chart for a Challenging Diagnosis.

Autoimmune pancreatitis is a chronic fibroinflammatory autoimmune mediated disease of the pancreas. Clinically, obstructive painless jaundice and upper abdominal pain are the main symptoms. Focal AIP is characterized by segmental involvement of pancreatic parenchyma and it is often radiologically represented by a pancreatic mass. In these cases, the diagnosis can be very challenging, since it may be easily confused with pancreatic cancer. Therefore, we suggest a combined approach of imaging tests as the diagnostic workup. EUS study combined with CEUS and elastography, if available, increases the accuracy of the method to rule out cancer. Moreover, the lesion should always be sampled under EUS guidance to obtain a cyto/histological diagnosis. The diagnostic workup should also include the use of diagnostic clinical criteria (extrapancreatic lesions, steroid response) and laboratory findings (CA 19.9 and IgG4 evaluations).